Ruth S. Palma, FNP-BC, CDCES
Family Medicine
Currently not accepting new patients
Ruth Palma, FNP-BC, CDCES, is a Family Medicine Nurse Practitioner at The Corvallis Clinic Asbury Building. With her extensive experience, she provides excellent care for patients of all ages.
Language(s) - English
Education
Master of Science in Nursing, University of Miami, Miami, FL, 1992; Bachelor of Science in Nursing, Florida Atlanta University, Boca Raton, FL, 1990
Experience
The Corvallis Clinic, Family Medicine, 2000 - Present; The Corvallis Clinic, Internal Medicine, 1995 - 2000; Primary Health Care Clinic, Salem, OR, 1994-1995; Orange County Public Health Unit, Orlando, Florida, 1992-1994
Certification
Certified Family Nurse Practitioner - American Nurse Credentialing Center; Certified Diabetes Educator - National Certification Board for Diabetes Educators; Good Clinical Practice (ICH Focus) for Investigators - Collaborative Institutional Training Initiative (CITI) Program
March 2018
Study: Protocol H9X-MC-GBGL
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of lnvestigational Dulaglutide Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus
(AWARD-11: Assessment of Weekly AdministRation of LY2189265 in Diabetes-11)
Sponsor: Eli Lilly
Role: Sub-Investigator
February 2017
Study: STUDY NUMBER: EFC14833
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Sponsor: Sanofi
Role: Sub-Investigator
January 2017
Eli Lilly H9X-MC-GBGJ A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of lnvestigational Dulaglutide Doses versus Placebo in Patients with Type 2 Diabetes on Metformin Monotherapy
Sponsor: Eli Lilly
Role: Sub-Investigator
April 2016
Study: MK0431-845: A Phase Ill, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared with the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine in Subjects with Type 2 Diabetes Mellitus
Sponsor: Merck
Role: Sub-Investigator
March 2017
Study: NN9535-4270 – SUSTAIN 8- semaglutide versus canagliflozin – Efficacy and safety of semaglutide versus canagliflozin as add-on to metformin in subjects with type 2 diabetes
Sponsor: Novo Nordisk
Role: Sub-Investigator
October 2015
Study: NN9924-4222: Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes
Sponsor: Novo Nordisk
Role: Sub-Investigator
December 2015
Study: NN9535-4216: Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes
Sponsor: Novo Nordisk
Role: Sub-Investigator
March 2014
Study: 1218.22: A multicenter, international, randomized, parallel group, double-blind, placebo-controlled CArdiovascular Safety & Renal Microvascular outcomE study with LINAgliptin 5mg once daily in patients with type 2 diabetes mellitus at high vascular risk. CARMELINA
Sponsor: Boehringer lngelhiem
Role: Sub-Investigator
November 2011
Study: A phase Ill randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of Bl 10773 25 mg/linagliptin 5 mg and Bl 10773 10 mg/linagliptin 5 mg Fixed Dose Combination tablets compared with the individual components (Bl 10773 25 mg, Bl 10773 10 mg, and linagliptin 5 mg) for 52 weeks in treatment na”ive and metformin treated patients with type 2 diabetes mellitus with insufficient glycaemic control.
Sponsor: Boehringer lngelhiem
Role: Sub-Investigator
September 2016
Study: Protocol H9X-MC-GBGJ (a): A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial
of lnvestigational Dulaglutide Doses versus Placebo in Patients with Type 2 Diabetes on Metformin Monotherapy
Sponsor: Eli Lilly
Role: Sub-Investigator
May 2017
Study: I8F-MC-GPGB: A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with Type 2 Diabetes Mellitus
Sponsor: Eli Lilly
Role: Sub-Investigator
October 2014
Study: I7I-MC-XNAA: Comparison of the Oxyntomodulin Analog, LY2944876, to Once-weekly Exenatide and to Placebo in Patients with Type 2 Diabetes Mellitus
Sponsor: Eli Lilly
Role: Sub-Investigator
November 2011
Study: A Comparison of LY2605541 Versus Insulin in Glargine as Basal Insulin Treatment in Combination with Oral Anithyperglycemia Medications in Insulin Naive Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study of 78 Weeks
Sponsor: Eli Lilly
Role: Sub-Investigator
February 2010
Study: A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patient with Type 2 Diabetes on Stable Doses of Metformin and Piolitazone.
Sponsor: Eli Lilly
Role: Sub-Investigato r
February 2010
Study: A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Subjects with Type 2 Diabetes Mellitus on Metformin.
Sponsor: Eli Lilly
Role: Sub-Investigator
February 2008
Study: A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (R05073031) compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin.
Sponsor: Eli Lilly
Role: Sub-Investigator
June 2008
Study: Safety and Efficacy of Exenatide in Patients with Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
Sponsor: Eli Lilly
Role: Sub-Investigator
